Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19
Status:
Recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Treatments for COVID-19 are urgently needed. Emricasan (EMR) is a pan caspase inhibitor.
Caspase-1 plays a role in a form of cell death called pyroptosis. EMR inhibits pyroptosis.
The Investigators have shown that peripheral blood lymphocytes of COVID-19 patients
overexpress caspase-1, providing evidence for pyroptosis. A recent European study corroborate
the Investigators finding as they have shown evidence for the activation of the inflammasome
in COVID-19.